Jennifer Vickers, MD
Dermatology · Austin, TXNPI 1184859225
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,980 of the $27,521 with a category attached, or 72.6%. Merz North America, Inc. accounts for 80.1% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $23,352, more than ten times the $580 reported in 2019.
Across 263 payments — averaging $104.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$22K
- AbbVie$1K
- E.r. Squibb & Sons, L.L.C.$453
- Sanofi$402
- UCB, Inc.$387
- Novartis$379
- plus $3K from 23 others
Across 1 payment — averaging $127.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$128
What the payments were for
- Consulting fees$19,98073%
- Travel & lodging$2,0007%
- Food & beverage$5,54120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 5 | $22,045 |
| AbbVie(2 entities) | 65 | $1,156 |
| E.r. Squibb & Sons, L.L.C. | 17 | $453 |
| Sanofi | 23 | $402 |
| UCB, Inc. | 12 | $387 |
| Novartis | 18 | $379 |
| Lilly USA, LLC | 14 | $337 |
| Regeneron Healthcare Solutions, Inc. | 18 | $313 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 13 | $279 |
| LEO Pharma Inc. | 11 | $251 |
| Incyte Corporation | 9 | $222 |
| Amgen | 11 | $215 |
| Galderma Laboratories, L.p. | 5 | $203 |
| Sun Pharmaceutical Industries Inc. | 6 | $110 |
| Botanix SB Inc | 4 | $95 |
| Arcutis Biotherapeutics, Inc. | 4 | $92 |
| Pfizer | 4 | $83 |
| Revance Therapeutics, Inc. | 1 | $71 |
| Dermavant Sciences, Inc. | 4 | $63 |
| Organon | 3 | $63 |
| Johnson & Johnson | 3 | $54 |
| Almirall LLC | 2 | $50 |
| Mayne Pharma Commercial LLC | 5 | $38 |
| VYNE Pharmaceuticals Inc. | 1 | $36 |
| Boehringer Ingelheim | 1 | $31 |
| Krystal Biotech Inc | 1 | $26 |
| LNHC, Inc | 1 | $25 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $20 |
| Journey Medical Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$16,400
- Bimzelx$128
- EPIDUO FORTE$126
- DUOBRII$107
- Humira$102
How this compares
$27,521 in reported general payments places this provider in the 85th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluocinonide | 16 | $559 |
| CiclopiroxCiclopirox Olamine | 26 | $208 |
| Triamcinolone Acetonide | 18 | $134 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Austin
- Edward LainAustin$2.5M
- Daniel CarrascoAustin$1.1M
- Dale SchaeferAustin$1M
- Heidi PratherAustin$543K
- Ali ShahbazAustin$413K
- Jennifer GordonAustin$150K
- Madalyn NguyenAustin$127K
- William CragunSan Antonio$2.2M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.